Do you routinely check tumor genomics, including POLE status for new endometrial cancers?

How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling? Given POLE mutation status can currently only be determined by next generation sequencing and incurs significantly added cost, when do you routinely order this testing given the 90 day global period for reimbursement?